Abstract:INTRODUCTION:The X-chromosome-linked inhibitor of apoptosis protein (XIAP) prevents apoptosis from activated transmembrane death receptors and confers tumour resistance to irradiation and chemotherapy. Despite the important oncologic implications, data concerning glioblastoma in this regard are few and isolated. The objective of this study was to examine the role of XIAP in the signalling pathway of TRAIL (tumour necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis in chemoresistant human glioblastoma cells.METHOD:Downregulators of XIAP, low-dose cisplatin, etoposide (VP 16) or second mitochondria-derived activator of caspase (Smac)-Tat peptide, were applied to 2 chemoresistant glioblastoma cell lines of fresh isolates to identify the impact of these sensitizing agents on the cytotoxicity of TRAIL. Hoechst staining for apoptotic nuclear morphology and Western blot analysis for the corresponding levels of proteins that regulate apoptotic pathways including XIAP were performed. The involvement of mitochondrial pathways marked by the release of cytochrome c or Smac/direct IAP (inhibitor of apoptosis protein)-binding protein with low P1 (DIABLO), or both, was assessed by confocal fluorescence microscopy.RESULTS:Downregulators of XIAP induced apoptosis in a dose-dependent manner with TRAIL in 1 chemoresistant glioblastoma cell line. Here, XIAP downregulation modulated by Smac-Tat peptide resulted in increased TRAIL-induced cell death. In addition, TRAIL was shown to enhance the translocation of Smac/DIABLO from mitochondria to the cytosol in cells that underwent apoptosis, which in turn neutralized XIAP activity. In comparison, the second chemoresistant glioblastoma cell line showed no regulatory XIAP effect. This finding correlates with the upstream effect of mutant p53 and BCL-X(L) status that were upregulated in this chemoresistant cell line.CONCLUSION:These results support the use of selective or tailored therapeutic strategies that synergistically sensitize chemoresistant glioblastoma to TRAIL-mediated apoptosis by administering appropriate XIAP downregulating agents.

Targeting KPNB1 Overcomes TRAIL Resistance by Regulating DR5, Mcl-1 and FLIP in Glioblastoma Cells

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

Molecular Mechanisms of Resistance to TRAIL-induced Apoptosis in Tumor

17-hydroxy wortmannin restores TRAIL's response by ameliorating increased beclin 1 level and autophagy function in TRAIL-resistant colon cancer cells.

Overcoming Acquired TRAIL Resistance in Human Colon Cancer by Proteasome Inhibitor Bortezomib

Bortezomib Overcomes Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part Through the Inhibition of the Phosphatidylinositol 3-Kinase/akt Pathway

KPNB1 inhibition disrupts proteostasis and triggers unfolded protein response-mediated apoptosis in glioblastoma cells.

PKCα–GSK3β–NF-κB Signaling Pathway and the Possible Involvement of TRIM21 in TRAIL-induced Apoptosis

Overcoming acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand by Bcl-XL small interfering RNA in human colon cancer

Overcoming TRAIL Resistance for Glioblastoma Treatment

BAY61-3606 Potentiates the Anti-Tumor Effects of TRAIL Against Colon Cancer Through Up-Regulating DR4 and Down-Regulating NF-κB.

Brd4 Inhibition Promotes Trail-Induced Apoptosis By Suppressing The Transcriptional Activity Of Nf-Kappa B In Nsclc

Hnrnpk Inhibits GSK3β Ser9 Phosphorylation, Thereby Stabilizing C-Flip and Contributes to TRAIL Resistance in H1299 Lung Adenocarcinoma Cells

Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5

Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL

IL13Rα2‑ and EGFR‑targeted pseudomonas exotoxin potentiates the TRAIL‑mediated death of GBM cells

Paclitaxel Enhances Tumoricidal Potential of TRAIL Via Inhibition of MAPK in Resistant Gastric Cancer Cells.

X-linked Inhibitor Regulating TRAIL-induced Apoptosis in Chemoresistant Human Primary Glioblastoma Cells.

C-Flip Degradation Mediates Sensitization of Pancreatic Cancer Cells to TRAIL-induced Apoptosis by the Histone Deacetylase Inhibitor LBH589.

Mir-133A Promotes TRAIL Resistance in Glioblastoma Via Suppressing Death Receptor 5 and Activating NF-κB Signaling

Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.